Grading the New Dyslipidemia Guidelines

Hi, everyone. I’m Dr Kenny Lin. I am a family physician and associate director of the Lancaster General Hospital Family Medicine Residency, and I blog at Common Sense Family Doctor.The 2026 Dyslipidemia Guideline What should we tell patients and learners about the new American College of Cardiology/American Heart Association (ACC/AHA) dyslipidemia guideline? The guideline contains many updates, beginning with replacing the Pooled Cohort Equations with the PREVENT calculator to estimate the risk of future cardiovascular events and guide lipid-lowering therapy. It lowers 10-year risk thresholds for statin therapy and expands the use of coronary artery calcium (CAC) scoring and lipoprotein (a) measurement to refine risk estimates. It brings back low-density lipoprotein (LDL) targets and recommends periodic lipid panel testing to confirm that lifestyle changes and pharmacotherapy are achieving LDL goals. A future commentary will discuss the strength of the evidence behind each of these key recommendations.Before delving into the recommendations, though, clinicians should assess the guideline’s overall trustworthiness. Tools for appraising guideline quality range from the comprehensive AGREE-II used by the American Academy of Family Physicians (AAFP) to the more streamlined G-TRUST. Two decades of writing and evaluating primary care guidelines lead me to home in on four key questions.1. Were the chairs and a majority of panelists free from conflicts of interest? Twelve of the 33 ACC/AHA guideline authors, but not the chair or vice chair, disclosed relevant financial conflicts of interest with drug or device companies. Fewer would have been better, but roughly 1 in 3 seems acceptable.Grade: Pass2. Were primary care organizations meaningfully involved? Although many other medical groups endorsed the ACC/AHA guideline, notably missing were the AAFP and the American College of Physicians (ACP), who together represent the majority of physicians who prevent cardiovascular disease in adults. Both organizations declined to participate due to concerns about the ACC/AHA's guideline development methodology.Grade: Fail3. Were the recommendations based on a systematic evidence review? The development of the dyslipidemia guideline did not involve independent systematic reviews of prespecified key questions. Instead, an “extensive evidence review” was performed in several databases, but without knowing the specific search terms, strategies, and inclusion criteria, there is no way for us to evaluate how truly comprehensive it was and whether selective study “cherry-picking” occurred. Other lipid management guidelines that relied on systematic reviews include the 2022 US Preventive Services Task Force and the 2025 US Department of Veterans Affairs/Department of Defense guidelines.Grade: Fail4. How were patient perspectives and preferences incorporated? One of the guideline authors is identified as a patient representative. That’s good, but a single person can’t speak for the whole population eligible for lipid-lowering therapies. Cardiologists see highly selected patients who are more willing than the typical primary care patient to take statins. To mitigate this biased perspective, the panel ought to have considered evidence regarding the degree of benefit that makes it worthwhile for most people to start a cholesterol-lowering drug. One study found that at a baseline 10-year risk of 10%, more than 40% of US adults would decline to take a statin even if doing so reduced their absolute risk to zero (in reality, it would reduce it by about 2.5%). That is consistent with some of my patients’ preferences, but the guideline’s treatment risk thresholds and absolute benefit projections are much lower.Grade: Low PassVerdict The ACC/AHA guideline authors had relatively few conflicts, but the guideline had little primary care input, did not rely on a systematic review, and did not consider evidence on patients’ treatment preferences. That doesn’t quite add up to a failing grade in my book, but these shortcomings mean that primary care clinicians should view each of the recommendations critically rather than simply accepting them as gospel.